Share
6,043 Posts.
lightbulb Created with Sketch. 295
clock Created with Sketch.
18/04/18
13:03
Share
Originally posted by roka
↑
Data Monitoring Committee (DMC) has performed another, scheduled review of the CHF trial data and recommended continuation of the trial without modification. Enrollment of this Phase 3 trial is expected to be completed by the end of 2018.
LVAD National Institutes for Health (NIH) Phase 2 trial has also completed enrollment with 12-month data read-out expected in the next quarter (Q3 CY18). Mesoblast is actively pursuing a potential accelerated entry pathway for MPC-150-IM into the cardiovascular market that may be provided by RMAT designation.
So, my take on this is both of these Tier 1 trials are confirmed on track with results coming in expected time-frames.
Expand
"...both of these Tier 1 trials are confirmed on track with results coming in expected time-frames."
In that case, it begs the question about the need for an announcement to that end.
Especially one that requires more than 2,000 word to communicate what took you less than 20 words.
Quite strange.
,